Clinical Trial Detail

NCT ID NCT00770263
Title Erlotinib and Temsirolimus for Solid Tumors
Recruitment Completed
Gender both
Phase Phase I
Variant Requirements Yes
Sponsors Washington University School of Medicine
Indications

Advanced Solid Tumor

adenoid cystic carcinoma

thyroid gland papillary carcinoma

squamous cell carcinoma

Therapies

Erlotinib + Temsirolimus

Age Groups: senior adult

Additional content available in CKB BOOST